FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR The team of over 60 scientists investigating the age-old mystery of... September 24, 2020 Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 COVID-19 Testing: What you need to know. August 19, 2020 Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... January 21, 2021 Load more HOT NEWS Fostering Growth and Creativity Through Journaling New drug available for rare thyroid cancer on NHS in England Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking Approximately 1 Million of New Maternal Orphans Due to Cancer in...
